Skip survey header

Novo Nordisk Product Theater Evaluation NPACE, December 9

1. I am a(n):
ACTIONS

1=Strongly Disagree, 4=Neutral, 7=Strongly Agree.
* Required Field.
2. As a result of this program, I intend to:
Reevaluate use of the GLP-1 RA therapy(ies) discussed for their associated benefits in my appropriate patients.
*This question is required.
1234567Not applicable
3. As a result of this program, I intend to:
Initiate my appropriate adult patients on GLP-1 RA therapy.
*This question is required.
1234567Not applicable
OBJECTIVES

1=Strongly Disagree, 4=Neutral, 7=Strongly Agree.
* Required Field.
4. As a result of this program, I am better able to:
Understand the outcomes trial(s) for the GLP-1 therapy(ies) discussed and the associated efficacy and safety results.
*This question is required.
1234567Not applicable
5. As a result of this program, I am better able to:
Understand the labeled indications for the GLP-1 RA therapy(ies) discussed.
*This question is required.
1234567Not applicable
PRESENTATION

1=Strongly Disagree, 4=Neutral, 7=Strongly Agree.
* Required Field.
6. The speaker delivered the presentation clearly and effectively. *This question is required.
1234567Not applicable
7. The speaker was knowledgeable about the content. *This question is required.
1234567Not applicable
OVERALL

1=Strongly Disagree, 4=Neutral, 7=Strongly Agree.
* Required Field.
8. Please rate your overall satisfaction with this program. *This question is required.
1234567Not applicable